A new vaccine based on the bacteria-fighting capabilities of the flagellin protein may protect against the bubonic plague. Read more.
Wake Forest’s Patricia Gallagher, PhD, and Ann Tallant, PhD, are developing Angiotensin-(1-7) into a powerful, dual fighting chemotherapeutic. Learn more.
Our scientists are developing tomorrow’s innovations in therapeutics, vaccines, medical devices and more. Get updates from Wake Forest Innovations.
Software developed by Wake Forest scientist Youngkyoo Jung, Ph.D., uses Fourier encoded arterial spin labeling to get a faster, clearer and more accurate brain scan.
Nanoparticle-induced hyperthermia delivers chemotherapeutic for abdominal cancer treatment quicker and with less damage to surrounding tissue.
Wake Forest researchers have developed a low-cost, versatile method for making organic thin-film transistors which shows promise for use in the electronics industry.
Wake Forest Innovations offers an extensive portfolio of technology licensing opportunities in biomedical and materials science.
Wake Forest Innovations supports your R&D needs through easy access to Wake Forest's unique research capabilities.
Wake Forest Innovations drives the creation of a new hub for innovation in biomedical and materials science and information technology.
A new milestone has been reached in regenerative medicine. Wake Forest Institute for Regenerative Medicine scientists have, for the first time, kept blood vessels open and flowing with blood in a replacement kidney study. Lab-grown replacement organs using scaffoldings derived from animal organs have become a widely accepted method in regenerative medicine. The process involves continue reading
A novel cancer drug developed by scientists at Wake Forest School of Medicine has successfully completed its Phase I clinical trial. The therapeutic, a unique approach to fighting cancer, aims to shut down or limit the activity of a cancer cell’s mitochondria – the “powerhouse” of the cell. This type of treatment is effective because continue reading